// App-Quantinova.ai

CT129 : A phase 1, dose escalation and expansion trial of guadecitabine (SGI-110), a second-generation hypomethylating agent in combination with pembrolizumab (MK3475) in patients with refractory solid tumors

Researchers

Presenter

  • Dionysis Papadatos-Pastos

Principal Investigators

  • Melek Akay

  • Malaka Ameratunga

  • Sanjena Mithra

  • Joo-Ern Ang

  • Sofia Levva

  • Reece Caldwell

  • Ruth Riisnaes

  • Mateus Crespo

  • Wei Yuan

  • George Seed

  • Bora Gurel

  • Ines Figueiredo

  • Rita Pereira

  • Susana Miranda

  • Anna Ferreira

  • Suzanne Carreira

  • Claudia Bertan

  • Chloe Baker

  • Ricardo Morilla

  • Robert Brown

  • Nahal Masrour

  • Toby Prout

  • Anna Zachariou

  • Alison Turner

  • Mona Parmar

  • Mark Van de Velde

  • Ben Jenkins

  • Christina Yap

  • Nina Tunariu

  • Udai Banerji

  • Juanita Lopez

  • Anna Minchom

  • Johann De Bono

Medical Centers

  • University College London Hospitals NHS Trust, London, United Kingdom

  • Royal Marsden, London, United Kingdom

  • Royal Marsden Hospital and Institute of Cancer Research, London, United Kingdom

  • Royal Marsden Hospital and Institute of Cancer Research, London, United Kingdom

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Solid malignancies

Biomarkers

  • Cluster of Differentiation 2AP

  • Cluster of Differentiation 4

  • Programmed death-ligand 1

  • Cluster of differentiation 8A

Drug/Treatment

  • guadecitabine

  • Pembrolizumab

  • SGI-110

Outcome

  • N/A

Study Design

  • Dose Escalation

Phase

  • I

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved